Pink Sheets: Regen Therapeutics PLC (REGUY) news stock charts
Regen Therapeutics PLC (REGUY/REGUY.PK) Penny Investment Summary:
ReGen Therapeutics Plc develops treatments for the management of cognitive decline and other neurological disorders, and rehabilitation after traumatic brain injury. It offers Colostrinin, a proline-rich polypeptide complex developed from colostrum, as a pharmaceutical for the treatment of Alzheimer’s disease and other neurological disorders. The company also develops constituent peptides of the Colostrinin as a nutraceutical for cognitive enhancement. In addition, ReGen Therapeutics provides Zolpidem, which is in Phase IIa clinical study for the treatment of insomnia. The company was founded in 1998 and is headquartered in London, the United Kingdom.REGEN THERAPEUTICS PLC-SPON (REGUY:OTC)
Snapshot of REGEN THERAPEUTICS PLC-SPON (REGUY)
|
OPEN
--
|
PREVIOUS CLOSE
--
|
|
|
DAY HIGH
--
|
DAY LOW
--
|
|
|
52 WEEK HIGH
-- - --
|
52 WEEK LOW
-- - --
|
|
|
MARKET CAP
--
|
AVERAGE VOLUME 10 D
0.0
|
|
|
EPS TTM
--
|
SHARES OUTSTANDING
2.3M
|
|
|
REGUY Does Not Pay Dividends
|
P/E TTM
--
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for REGEN THERAPEUTICS PLC-SPON (REGUY)
ReGen Therapeutics plc, Annual General Meeting, Mar 11, 2010
ReGen Therapeutics plc expected to Report Fiscal Year 2009 Results on May 27, 2010. This event was calculated by Capital IQ (Created on January 26, 2010).
ReGen Therapeutics plc has entered into an exclusive test marketing agreement with PRG Nutraceuticals for the retail distribution of Colostrinin in the UK. PRG Nutraceuticals aims to launch Colostrinin in September 2009 under the product name MemoryAid. The agreement is for an initial term of six months and is on substantially the same commercial terms as the company's other test marketing agreements in other territories. If the test marketing is successful, PRG Nutraceuticals will then be made ReGen's exclusive distributor for the UK. The board believes that the proposed arrangements with PRG Nutraceuticals will enable the company to develop its interests in the UK with an effective partner at no financial risk to the company.
Regen Therapeutics PLC financial resources
REGUY Competitors
| Company | Last | Change |
| AstraZeneca PLC | 2,941 GBp | +30.50 |
| GlaxoSmithKline PLC | 1,272 GBp | -0.50 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | REGUY | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | 3,383.3x |
|
| Price/Book | 24.2x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | 7,542.9x |
|
|
REGUY |
||
REGUY transactions
| Type Date |
Target |
|
Private Placement
January 14, 2010 |
-- |
|
Private Placement
October 30, 2009 |
-- |